Phase 4 N=114 Arthralgia During Anastrozole Therapy for Breast Cancer
Early Breast Cancer
Primary: Number of Participants With New Events of Arthralgia — 37 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=62 Factors Associated With Radiographic Pathophysiology for Trapeziometacarpal Arthrosis in Patients Not Seeking Care for This Condition
Trapeziometacarpal Arthrosis
Primary: Factors Associated With Eaton Classification of Trapeziometacarpal Arthrosis: Age — 61; 66; 75 Years
Phase 3 N=164 A Study on Visco-antalgic Intra-articular Administration in Symptomatic Knee Osteoarthritis
Knee Osteoarthritis
Primary: Change From Baseline in WOMAC VA3.1 Pain Subscale Score at Month 6 — -23.6; -14.1 mm — p=0.141
Phase 3 N=227 Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
Arthralgia · Breast Cancer · Hot Flashes
Primary: Change in Item #3 (Average) of the Brief Pain Inventory (BPI) Average Pain From Baseline to Month 3 — -1.9; -2.0 score on a scale — p=0.4952
N/A N=36 Durolane SJ for Treatment of Rhizarthrosis
Rhizarthrosis
Primary: Change From Baseline in Pain Measured by the VAS Scale — -2.00 units on a scale
N/A N=1,261 Survey of Osteoarthritis Real World Therapies (MK-0663-140)
Osteoarthritis
Primary: Percentage of Participants Who Reported Adequate vs. Inadequate Pain Relief at Baseline — 46.2; 53.8 Percentage of Participants
Phase 4 N=261 Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer
Breast Cancer
Primary: Number of Participants Discontinuing Due to Grade 2 or Higher Arthralgia-myalgia. — 25 Participants
Phase 3 N=40 Impact of TheraWorx Foam on Symptom Relief in Thumb Arthritis
Arthritis
Primary: Numeric Pain Rating Scale — 1.7; 2.4; 3.2 units on a scale — p=0.6
N/A N=20 Geniculate Artery Embolization for the Treatment of Knee Pain
Osteoarthritis Of Knee
Primary: Patient Function (Units on a Scale) — 31 units on a scale
N/A N=80 Knee Bracing for People With Patellofemoral Osteoarthritis
Knee Osteoarthritis
Primary: Change in Pain on the VIsual Analog Scale (VAS) — -.068 change in units on a scale from baseline
Phase 2 N=260 Exploratory Study of PENNSAID Gel to Treat Symptoms of Knee Osteoarthritis
Osteoarthritis of the Knee
Primary: Pain When Walking On A Flat Surface — 0; 1; 8; 4 Participants
Phase 2 N=53 Glucosamine and Chondroitin for Aromatase Inhibitor Induced Joint Symptoms in Women With Breast Cancer
Breast Cancer · Joint Pain
Primary: Change in WOMAC Score — 24.9 Score on a scale — p=0.004
N/A N=34 Inflammation and Insulin Resistance in Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Disease Activity Score Based on 28-joint Disease Activity Score (DAS28) — 4.40; 4.03; 4.57; 4.48 units on a scale
Phase 2 N=41 A Pilot Study Assessing the Treatment Responsiveness of a Novel Osteoarthritis Stiffness Scale
Osteoarthritis, Knee
Primary: Sum of Change in Brief Arthritis Stiffness Scale (BASS) Scores Over the 4-day Treatment Period — -12.6; -13.6; -11.7; -2.3 Scores on a scale
N/A N=71 Molecular Pathways Involved in Knee Pain
Knee Osteoarthritis · Knee Pain Chronic
Primary: Pain Sensitivity: Pressure Pain Detection Threshold (PPT) — 252.58; 266.17 kPa
Phase 1 N=32 A Study in Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Number of Participants With Clinically Significant Effects — 0; 0; 0; 0 participants
N/A N=38 Geniculate Artery Embolization for Treatment of Osteoarthritis
Osteoarthritis
Primary: Percentage Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) - Pain Score — -50.1 Percentage change
N/A N=360 Staying Positive With Arthritis Study
Arthritis
Primary: Self-reported Pain From Baseline to 1, 3, and 6 Months Post-intervention — 50.24; 47.42; 45.42; 43.57 units on a scale — p=0.791
Phase 4 N=150 Effects on the Pain of an Infiltration by Acid Hyaluronic Association and Corticoids Versus Only Corticoids in the Rhizarthrosis.
Rhizarthrosis
Primary: Analogical Visual Scale of Pain (VAS) — -1.66; -2.65 centimeter
N/A N=1,102 Prospective Multicenter Non-interventional Study in Patients With Knee or Hip Osteoarthritis Having a Theraflex Treatment
Osteoarthritis
Primary: Changes in the Pain Intensity Subscale — 18.07; 15.59; 20.92; 20.06 Scores on a scale
Phase 2 N=157 Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study In Subjects With Osteoarthritic Pain Of The Knee
Osteoarthritis, Knee
Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Domain Score at Week 2 — -3.64; -3.15 Units on a scale — p=0.39
N/A N=823 Weight Loss and Exercise for Communities With Arthritis in North Carolina
Osteoarthritis
Primary: Knee Pain — 5.0; 5.5 score on a scale
Phase 4 N=500 Patient-Reported Effectiveness and Safety of Etoricoxib in Osteoarthritis (OA)(0663-113)
Pain
Primary: The Percentage of Participants Achieving ≥30% Decrease From Baseline in Pain Intensity as Measured by WOMAC (Western Ontario and McMaster Universities Osteoarthritis…
N/A N=144 Intra-articular Polyacrylamide Hydrogel in Knee Osteoarthritis
Osteoarthritis
Primary: Change of the Total WOMAC Score (WOMAC-T) — -624.12; -444.82; -605.61; -426.31 score on a scale — p=0.00030
N/A N=18 Yoga as Self-Care for Arthritis in Minority Communities
Rheumatoid Arthritis · Arthritis
Primary: Self-Efficacy Exercise — 6.1 units on a scale
Phase 2 N=39 A Study of LY2828360 in Patients With Osteoarthritic Knee Pain
Osteoarthritis, Knee
Primary: Change From Baseline to 4 Week Endpoint in Weekly Mean of Daily 24-Hour Average Pain Scores (APS) — -0.90; -1.20 units on a scale
Phase 3 N=256 Duloxetine vs. Placebo in the Treatment of Osteoarthritis Knee Pain
Osteoarthritis Knee Pain
Primary: Change in Brief Pain Inventory (BPI) 24-hour Average Rating — -1.80; -1.12; -2.47; -1.41 units on a scale — p=<0.001
Phase 2 N=42 A Phase 1/2A, Single Dose Study Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The Knee
Osteoarthritis, Knee
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 9; 4; 9; 8 Participants
N/A N=23 Skeletal Muscle Atrophy and Dysfunction Following Total Knee Arthroplasty
Knee Osteoarthristis
Primary: Cross-sectional Area (CSA) of Muscle Fibers — 2680; 2377; 2028; 1882 micron squared
Phase 3 N=714 Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee
Osteoarthritis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 394 Participants